National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai
The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...
Policy / Regulatory
NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...
Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says
A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...
NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign
The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...
China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase
The National Healthcare Security Administration (NHSA) released the National Long‑Term Care Insurance Service Catalog (Trial),...
Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that...
Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
President Donald J. Trump’s administration has opened new investigations under Section 232 of the Trade Expansion Act, targeting...
China Drug Procurement: Centralized Rules Shape 11th Round Of VBP
The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...
National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation
The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...
NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle
The National Healthcare Security Administration (NHSA) announced today that the expert review for the 2025...
China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...
Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices
The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...
NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications
The National Medical Products Administration (NMPA) has just published the 96th edition of its Reference...
FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...
NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...
China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls
At a State Council Information Office press conference, Deputy Director of the National Health Commission...
China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings
The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...
China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach
The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...
NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight
The National Medical Products Administration (NMPA) issued a draft of its Compliance Guidelines for Online...
FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs
The U.S. Food and Drug Administration (FDA) today announced a new “green list” import alert...